1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
Holly LaFon
Holly LaFon
Articles (5087) 

Baron Funds Comments on Grifols SA

August 30, 2012 | About:

From Baron Funds' second quarter commentary:

Grifols SA (NASDAQ:GRFS) manufactures and sells plasma derivative healthcare products to hospitals and physicians globally. Grifols' NASDAQ-traded ADR increased over 24% during the quarter. Grifols' plasma proteins are an essential medical treatment for patients with primary immune deficiency, neurological diseases or hemophilia. Few companies can manufacture these treatments with a high degree of quality and consistency. Healthy demand for the product, coupled with a strong pricing environment, helped Grifols during the quarter.We continue to believe that Grifols will generate strong synergies from its 2011 acquisition of U.S.-based Talecris, and that Grifols will become significantly more profitable going forward. (Aaron Wasserman)


Rating: 3.3/5 (8 votes)

Comments

Please leave your comment:


GuruFocus Mobile App Available


Select portfolio(s):

  • Loading...

Why you are interested?

Your selection and notes will be stored in your portfolio.

Login to add portfolio
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK